title: Effects of Intravitreal Ranibizumab in the Treatment of Retinopathy of Prematurity in Chinese Infants.
abstract: To evaluate the efficacy associated with intravitreal ranibizumab in the treatment of retinopathy of prematurity (ROP).
  
  
  
  A retrospective case series study. Infants diagnosed with Type 1 ROP, or aggressive posterior ROP (AP-ROP) were enrolled in the study. All infants in the study received intravitreal ranibizumab (0.25 mg/0.025 ml) as the initial treatment. Follow-up examinations were performed the day after treatment, then weekly for 1 month, bi-monthly for two additional months, then monthly until vascularization of zone III occurred. Additional treatments were initiated in cases of disease recurrence.
  
  
  
  Thirty-three premature infants (a total of 66 eyes) receiving intravitreal ranibizumab were included. The mean birth weight was 1291 ± 211 g (range: 650-1650 g) and the mean gestational age was 29.8 ± 1.6 weeks (range: 27.0-33.6 weeks). The mean gestational age at the time of the first injection was 35.8 ± 1.6 weeks (range: 32.7-38.4 weeks). The mean follow-up time was 12.9 ± 4.9 months (range: 6-22 months). Single injections were administered to 58 eyes (87.9%), whereas eight eyes (12.1%) received additional treatments. Recurrence was observed in eight eyes (12.1%), with a mean time to recurrence of 6.9 ± 1.8 weeks (range: 4-8 weeks).
  
  
  
  Intravitreal ranibizumab is effective for the treatment of retinopathy of prematurity, although a small amount of patients recurred. Compared with intravitreal bevacizumab, a higher incidence and shorter time to recurrence were observed after intravitreal ranibizumab treatment, thus longer and more frequent follow-ups are needed.
authors.affiliation: a Ophthalmic Center , Renmin Hospital of Wuhan University , Wuhan , Hubei Province , China.
authors.forename: Zuohuizi
authors.initials: Z
authors.lastname: Yi
authors.affiliation: a Ophthalmic Center , Renmin Hospital of Wuhan University , Wuhan , Hubei Province , China.
authors.forename: Yu
authors.initials: Y
authors.lastname: Su
authors.affiliation: a Ophthalmic Center , Renmin Hospital of Wuhan University , Wuhan , Hubei Province , China.
authors.forename: Yunyun
authors.initials: Y
authors.lastname: Zhou
authors.affiliation: a Ophthalmic Center , Renmin Hospital of Wuhan University , Wuhan , Hubei Province , China.
authors.forename: Hongmei
authors.initials: H
authors.lastname: Zheng
authors.affiliation: a Ophthalmic Center , Renmin Hospital of Wuhan University , Wuhan , Hubei Province , China.
authors.forename: Meihong
authors.initials: M
authors.lastname: Ye
authors.affiliation: a Ophthalmic Center , Renmin Hospital of Wuhan University , Wuhan , Hubei Province , China.
authors.forename: Yonghong
authors.initials: Y
authors.lastname: Xu
authors.affiliation: a Ophthalmic Center , Renmin Hospital of Wuhan University , Wuhan , Hubei Province , China.
authors.forename: Changzheng
authors.initials: C
authors.lastname: Chen
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D002681:China / Q000453:epidemiology; D004305:Dose-Response Relationship, Drug; D005260:Female; D005500:Follow-Up Studies; D005865:Gestational Age; D006801:Humans; D015994:Incidence; D007223:Infant; D007231:Infant, Newborn; D058449:Intravitreal Injections; D008297:Male; D000069579:Ranibizumab / Q000008:administration & dosage*; D012178:Retinopathy of Prematurity / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology; D012189:Retrospective Studies; D013997:Time Factors; D016896:Treatment Outcome; D014792:Visual Acuity
chemical_list: D020533:Angiogenesis Inhibitors; D000069579:Ranibizumab
keywords: Efficacy; ranibizumab; recurrence; retinopathy of prematurity; vascular endothelial growth factor